About this episode
Dr. Raj Mehra joins the podcast today to discuss the ongoing clinical trials that Seelos Therapeutics is conducting to investigate Racemic Ketamine as an effective drug candidate for treating patients with Acute Suicidal Ideation and Behavior -
The suicide crises in the United States and beyond is an epidemic in itself, and Seelos Therapeutics is working towards delivering the worlds first FDA-approved ketamine treatment for individuals with ASIB.
In this episode, Dr. Mehra discusses the clinical data suggesting that R-Ketamine is an effective treatment to help mitigate the suicide crises, as well as the Seelos Therapeutics patenting strategy and and path that a drug must take in order to be adapted into medicalized use.
Please consider rating and reviewing the podcast wherever you're listening.
Hosted on Acast. See acast.com/privacy for more information.
Get every episode summarized
Each time Mycopreneur publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Mycopreneur
Lee Carroll: Ergothioneine in Support of Psychedelic Therapy
Mycopreneur
Adam Miezio: Psychedelics in the Epstein Files
Mycopreneur
Robert Gallery: Ibogaine For Athletes with Traumatic Brain Injuries
Mycopreneur
Melanie Tremblay: The Hidden Dangers of AI-Generated Mushroom Claims
Mycopreneur